Tectonic Therapeutic, Inc.
TX45
Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF)
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for TX45 in Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“APEX patient enrollment is nearing completion with topline data anticipated in late Q4 2026 or early Q1 2027.”